5.95
price up icon15.31%   0.79
after-market After Hours: 5.95
loading
Agenus Inc stock is traded at $5.95, with a volume of 2.50M. It is up +15.31% in the last 24 hours and up +100.34% over the past month. Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$5.16
Open:
$5.19
24h Volume:
2.50M
Relative Volume:
2.67
Market Cap:
$163.15M
Revenue:
$160.43M
Net Income/Loss:
$-227.64M
P/E Ratio:
-0.0865
EPS:
-68.77
Net Cash Flow:
$-170.79M
1W Performance:
+73.47%
1M Performance:
+100.34%
6M Performance:
+66.20%
1Y Performance:
-64.07%
1-Day Range:
Value
$5.18
$6.35
1-Week Range:
Value
$3.4582
$6.35
52-Week Range:
Value
$1.38
$18.74

Agenus Inc Stock (AGEN) Company Profile

Name
Name
Agenus Inc
Name
Phone
781-674-4410
Name
Address
3 FORBES ROAD, LEXINGTON, MA
Name
Employee
316
Name
Twitter
@Agenus_Bio
Name
Next Earnings Date
2024-12-05
Name
Latest SEC Filings
Name
AGEN's Discussions on Twitter

Compare AGEN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AGEN
Agenus Inc
5.95 87.73M 160.43M -227.64M -170.79M -68.77
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.69B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 114.81B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.232 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.34 6.60B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 65.36B 14.09B 4.50B 2.96B 39.28

Agenus Inc Stock (AGEN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-04-25 Upgrade H.C. Wainwright Neutral → Buy
Jul-19-24 Downgrade Robert W. Baird Outperform → Neutral
Jul-18-24 Downgrade H.C. Wainwright Buy → Neutral
Jul-18-24 Downgrade William Blair Outperform → Mkt Perform
Jun-06-23 Initiated Robert W. Baird Outperform
Feb-28-23 Resumed H.C. Wainwright Buy
Sep-28-22 Initiated SMBC Nikko Outperform
Dec-16-21 Initiated H.C. Wainwright Buy
Nov-19-19 Resumed B. Riley FBR Buy
Apr-22-19 Initiated B. Riley FBR Buy
Oct-28-16 Downgrade H.C. Wainwright Buy → Neutral
Oct-27-16 Reiterated Maxim Group Buy
Mar-11-16 Upgrade Maxim Group Hold → Buy
Dec-16-15 Initiated Jefferies Buy
Oct-27-15 Downgrade Maxim Group Buy → Hold
Jul-27-15 Reiterated MLV & Co Buy
Jun-11-15 Initiated Oppenheimer Outperform
Jan-12-15 Reiterated Maxim Group Buy
Jan-09-15 Reiterated MLV & Co Buy
Jan-09-15 Reiterated Maxim Group Buy
Dec-19-14 Reiterated Maxim Group Buy
May-08-14 Reiterated Maxim Group Buy
Mar-14-14 Reiterated MLV & Co Buy
Oct-08-13 Reiterated Maxim Group Buy
Jan-05-12 Initiated William Blair Outperform
Dec-01-11 Initiated Global Hunter Securities Buy
View All

Agenus Inc Stock (AGEN) Latest News

pulisher
11:57 AM

H.C. Wainwright Upgrades Agenus (AGEN) Stock to Buy - MSN

11:57 AM
pulisher
05:35 AM

Zydus Lifesciences venture capital arm to acquire stake in Agenus for USD 16 million - Medical Dialogues

05:35 AM
pulisher
Jun 05, 2025

Zydus enters global biologics CDMO market with $75m facility acquisitions - BioProcess International

Jun 05, 2025
pulisher
Jun 05, 2025

Baird Lifts Agenus (AGEN) PT to $6, Maintains Neutral Rating - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

Agenus (NASDAQ:AGEN) Upgraded to “Buy” at HC Wainwright - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Agenus (NASDAQ:AGEN) Price Target Raised to $6.00 at Robert W. Baird - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Zydus Lifesciences to acquire India, Sri Lanka rights for Agenus cancer immunotherapy BOT/BAL - Medical Dialogues

Jun 05, 2025
pulisher
Jun 05, 2025

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US - 뉴스와이어

Jun 05, 2025
pulisher
Jun 04, 2025

Agenus Announces Strategic Collaboration with Zydus - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus climbs on deal with India’s Zydus for cancer therapy BOT/BAL - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus IncSigns Partnership Agreements With Zydus Lifesciences - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus Life To Buy Agenus' US Facilities For $75 Million For Entry In Biologics CDMO - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash OverhangAgenus (NASDAQ:AGEN) - Benzinga

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus Shares Rise After Upgrade From HC Wainwright - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright upgrades Agenus stock on strategic collaboration - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright upgrades Agenus stock on strategic collaboration By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus (AGEN) Price Target Raised by Baird as Neutral Rating Mai - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus (AGEN) Price Target Raised by Baird as Neutral Rating Maintained | AGEN Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

HC Wainwright & Co. Upgrades Agenus (AGEN) - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus (AGEN) Upgraded to 'Buy' by HC Wainwright & Co. | AGEN Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus (AGEN) Stock Price Target Increased by Baird | AGEN Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus and Zydus sign agreements for botensilimab and balstilimab - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus gets rights for next gen I-O platforms from Agenus - The Pharma Letter

Jun 04, 2025
pulisher
Jun 04, 2025

HC Wainwright Upgrades Agenus to Buy From Neutral, $25 Price Target - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus (AGEN) Boosted to Buy Following Key Zydus Partnership | A - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus (AGEN) Boosted to Buy Following Key Zydus Partnership | AGEN Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus, Agenus team up for next-gen cancer immunotherapies - Healthcare Radius

Jun 04, 2025
pulisher
Jun 04, 2025

Jane Street Group LLC Raises Stock Position in Agenus Inc. (NASDAQ:AGEN) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus to acquire Agenus’ US manufacturing facilities, forays into global biologics CDMO business - Indian Pharma Post

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus Lifesciences acquires Agenus Biologics facilities in US, enters global CDMO market - Express Pharma

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus to enter global biologics CDMO business: Plans to acquire Agenus' U.S. manufacturing facilities to accelerate development of innovative therapies - StreetInsider

Jun 04, 2025
pulisher
Jun 04, 2025

Agenus inks $141M deal with Zydus for cancer drugs, facilities By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Zydus acquires Agenus biologics facilities for CDMO expansion By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Zydus Lifesciences to acquire Agenus’s two biologics units for USD 125M - Medical Buyer

Jun 03, 2025
pulisher
Jun 03, 2025

With plans to acquire US-based genus Inc, Zydus Lifesciences set to enter the global biologics CDMO business - financialexpress.com

Jun 03, 2025
pulisher
Jun 03, 2025

Zydus Lifesciences Subsidiary Zynext to Acquire 5.9% Stake in Agenus for $16 Million - India Infoline

Jun 03, 2025
pulisher
Jun 03, 2025

Zydus enters global biologics CDMO business, plans to acquire Agenus’ U.S. manufacturing facilities to accelerate development of innovative therapies - Equity Bulls

Jun 03, 2025
pulisher
Jun 03, 2025

Zydus announces plan to acquire US manufacturing units of Agenus Inc - The Indian Express

Jun 03, 2025
pulisher
Jun 03, 2025

Agenus Inc. announced that it expects to receive $15.75 million in funding from Zydus Lifesciences Limited - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Zydus to acquire US biotech firm Agenus’ facilities in California - The Economic Times

Jun 03, 2025
pulisher
Jun 03, 2025

Agenus Stock Is Trading Higher Tuesday: What's Going On? - Benzinga

Jun 03, 2025
pulisher
Jun 03, 2025

Zydus to acquire 2 biologics manufacturing units in U.S. from Agenus for $125 million - The Hindu

Jun 03, 2025
pulisher
Jun 03, 2025

Agenus to Sell US Manufacturing Facilities to Zydus Lifesciences - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Zynext Ventures acquires stake in Agenus, expands its immuno-oncology pipeline and global reach - The Malaysian Reserve

Jun 03, 2025
pulisher
Jun 03, 2025

Zydus buys Agenus' biologics plants in US for $125 mn, licenses cancer therapy | Company Business News - Mint

Jun 03, 2025
pulisher
Jun 03, 2025

Zydus bolsters global biologics play with Agenus acquisition, immuno-oncology licensing pact - Fortune India

Jun 03, 2025
pulisher
Jun 03, 2025

Zydus inks pact to acquire stake in US firm to enter contract manufacturing space - theweek.in

Jun 03, 2025
pulisher
Jun 03, 2025

Zydus Lifesciences to Enter the Global CDMO Business - Contract Pharma

Jun 03, 2025
pulisher
Jun 03, 2025

Zydus Life To Buy Agenus US Facilities For $75 Million For Entry In Biologics CDMO - NDTV Profit

Jun 03, 2025
pulisher
Jun 03, 2025

Agenus (AGEN) Rises on Zydus Partnership to Boost Cancer Therapy - GuruFocus

Jun 03, 2025

Agenus Inc Stock (AGEN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.15
price up icon 1.30%
$584.68
price up icon 0.75%
$308.75
price up icon 1.19%
$37.33
price up icon 2.30%
$4.68
price down icon 3.35%
$492.00
price up icon 1.78%
Cap:     |  Volume (24h):